Maraviroc plus optimised background therapy vs optimised background therapy for non-alcoholic fatty liver disease in people living with HIV-1

Phase 4, randomised, open-label trial of aprepitant in metabolic dysfunction-associated steatotic liver disease (MASLD) and Human immunodeficiency virus infection type 1 (2 arms), sponsored by Brighton and Sussex University Hospitals NHS Trust. Primary endpoint: Feasibility and acceptability of adding maraviroc to optimised background therapy. Status: unknown.